




(IV)




(VII)




(VIII)




(IX)




(X)




(XIII)



(XV)



(XIX)




(XXV)


and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof and combinations thereof.

5. (Amended) A method of treating [disease] osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, premenstrual syndrome, prostatic carcinoma, benign prostatic hyperplasia, pulmonary hypertension, reperfusion damage, rheumatoid arthritis, osteoarthritis, seborrhea, senile gynecomastia, testosterone deficiency, Turner's syndrome, uterine fibrosis, atrophic vaginitis, incontinence, uterine cancer, hirsutism, bulimia, anorexia, hypoactive sexual desire, sexual arousal disorder, dyspareunia, vaginismus, prolapse, urinary tract infections, stroke, myocardial infarction, acute or chronic renal failure, peripheral arterial occlusive disease, Raynaud's Phenomenon, cancers of the ovary, liver, and pancreas, as well as desmoid cancer, glioma, and renal cell carcinoma, or promoting wound healing, increasing the frequency of orgasms, or

lowering vaginal pH comprising administering to a subject in need thereof, an effective amount of a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



wherein R₁ is selected from




NH(CH₂)₃COR₆;

R₅ is selected from H, or CH₃;

R₂, R₃, R₄ and R₇ are the same or different and are selected from H and OR₅; and


R₆ is selected from -OH, or -NHCH₂COOH,

provided that:

- (a) if R₁ is , or -NH(CH₂)₃COOH and
- (b) R₂ is OH or OCH₃ and R₃ and R₇ are H, or if R₁ is as defined in (a) above and
- (c) R₂ and R₇ are H and R₃ is OH or OCH₃,

then R₄ is not H;

and further provided that when R₂, R₃, R₄ and R₇ are H, then R₁ is not



or an optical, stereo, regio or configurational isomer or geometric isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof.

An Information Disclosure Statement is being filed concurrently with this amendment. The examiner is requested to consider each document listed; however, applicants wish to highlight the following two publications: Proceedings: The 45th ASMS Conference on Mass Spectrometry and Applied Topics, June 1-5, 1997, Palm Springs, CA; and Proceedings: The 46th ASMS Conference on Mass Spectrometry and Applied Topics, May 31-June 4, 1998, Orlando, FL. A separate paper is attached hereto that details the status of the claims and sets forth the support for the claim changes.

Applicants believe that, in view of the amendments and remarks made above, this application is in condition for allowance. Reconsideration and allowance of claims 2, 5-10 is respectfully requested.

Date: 5/30/2003

By: Todd M. Crissey

Todd M. Crissey
Registration No. 37,807
Pfizer Inc.
Patent Department,
MS 8260-1611
Eastern Point Road
Groton, CT 06340
Phone: (860) 715-4331
Fax: (860) 441-5221

Status of Claims and Support for Claim Changes

Claim Number	Status of Claims	Support for Changes
1	canceled	
2	pending (amended)	Original claim 2 and compounds X, XIII and XV in Table 2, columns 13-14.
3	canceled	
4	canceled	
5	pending (amended)	Original claim 5 and column 16, lines 23-44.
6	pending	
7	pending	
8	pending	
9	pending	
10	pending	
11	cancel	